Breast PET Feasibility (Breast PET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03198442|
Recruitment Status : Recruiting
First Posted : June 26, 2017
Last Update Posted : February 15, 2019
|Condition or disease||Intervention/treatment||Phase|
|Breast Neoplasm Female||Procedure: F-18 FDG breast PET scan||Not Applicable|
This study involves a single trial visit the Royal Free Hospital for imaging. Participants will need to lie flat for up to 30 minutes on the PET-CT camera and up to 30 minutes on the MAMMI. They will be advised not to take part in this study if they are unable to lie flat on their back and their front for this length of time or if they are claustrophobic. They will be offered the opportunity to see the PET-CT scanner and the MAMMI before deciding to consent to the trial.
Participants will be exposed to a radiation dose from the radioactive tracer F-18 FDG that is injected into the vein before the scan and from the CT exposures during the scan. The dose associated with the injection of about 3 MBq/kg of F-18 FDG is in the range of 4-7mSv. A CT will be performed over the thorax to allow attenuation correction of PET images and localisation of tracer uptake. The dose from the thorax CT will be patient dependent but the mean dose to a patient undergoing this type of scan is 2.1mSv. A whole body CT will be performed from the base of the skull to mid-thigh to plan the bed positions for the whole body emission scan and to allow attenuation correction of PET images and localisation of tracer uptake. The dose from the whole body CT will be patient dependent but the mean dose to a patient undergoing this type of scan is 5.2mSv.The total radiation dose participants will be exposed to is in the range of 11.3-14.3mSv. This is equivalent to 4-5.3 years of background radiation to which individuals in the UK are regularly exposed. This would amount to an increased lifetime risk of cancer of approximately 1 in 1250 in a standard population. These risks are compared to a normal lifetime risk of cancer of 1 in 3.
The half-life of F-18 is 110 minutes. The duration of the scan will be up to 120 minutes post injection. The activity within the patient will have reduced by more than 50% through radioactive decay alone by the time they leave the department and will be further reduced by excretion in urine. As with standard clinical administration of F-18, patients will not need to follow any special restrictions once leaving the department.
The CT scanning protocols used in the trial PET-CT are the standard clinical protocols used in the nuclear medicine department and have been developed with a view to minimising the dose to the patient as far as possible. All women of childbearing potential will undergo a pregnancy test on the day of the scan before the injection of the radioactive tracer in order to rule out any risk to a potential foetus. Any woman of childbearing potential who is found to be pregnant or will not consent to a pregnancy test will be excluded from the trial.
Very rarely, individuals may develop an allergic reaction to the PET tracer. No serious adverse reactions to this tracer have been reported. Patients may experience some discomfort from having a needle inserted into their arm/hand in order to have the tracer injected. Occasionally the vein may become inflamed or infected, or they may experience bruising at the insertion site. All efforts will be made to avoid or minimise any discomfort or other adverse effects from these procedures.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Small cohort.|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Role of Dedicated Breast PET in the Characterisation of Indeterminate Breast Lesions on MRI Requiring a Second-look Ultrasound - a Feasibility Study|
|Actual Study Start Date :||October 5, 2016|
|Estimated Primary Completion Date :||October 5, 2019|
|Estimated Study Completion Date :||December 21, 2019|
Experimental: Breast PET
PET imaging of breast with patient in prone position.
Procedure: F-18 FDG breast PET scan
Other Name: MAMMI
- Recruitment rate [ Time Frame: Two years. ]To assess the feasibility and acceptability to patients of F-18 FDG breast PET scans, by determining how many patients can be recruited over two years.
- Comparison with standard-of-care assessments [ Time Frame: Two weeks ]To compare results of breast PET to ultrasound, breast MRI and pathology
- Eligibility barriers to recruitment [ Time Frame: Two years. ]To determine which eligibility criteria are barriers to recruitment of patients to a study of F-18 FDG breast PET scans.
- Comparison with whole-body PET [ Time Frame: Two weeks ]To compare the results obtained from F-18 FDG PET CT and breast PET scans
- Sample size calculation [ Time Frame: Two years. ]To estimate outcome standard deviations to inform sample size calculations for a definitive trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03198442
|Contact: Norman Williams, PhDemail@example.com|
|Royal Free Hospital||Recruiting|
|London, United Kingdom, NW3 2QG|
|Contact: Thomas Wagner 020 3758 2000|
|Principal Investigator: Thomas Wagner|
|Principal Investigator:||Thomas Wagner||Royal Free Hospital NHS Foundation Trust|